FGF21 and obesity due to melanocortin 4 receptor deficiency: Clinical trials have demonstrated the potential of recombinant FGF21 for the treatment of type 2 diabetes, obesity, and other comorbidities, but its physiological role in atherosclerosis (AS) has only gained attention in recent years (16, 17).